Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Global Renal Biomarker Market Research and Forecast 2018-2023Global Renal Biomarker Market, Size, Share, Market Intelligence, Company Profiles, Market Trends, Strategy, Analysis, Forecast 2018-2023
The renal biomarker market can be segmented on the basis of, type, diagnostic technique and end users. Based on the type, the renal biomarker market is bifurcated as diagnostic biomarkers, prognostic biomarkers, predictive biomarkers, and pharmacodynamic biomarkers. On the basis of diagnostic technique, the market is diversified as ELISA, colorimetric assay, liquid chromatography – mass spectrometry and particle enhanced turbidimetric immunoassay. Based on the end users, the renal biomarker market is sub-divided as hospitals, diagnostic labs and research centers. Among the diagnostic technique, ELISA is expected to hold the largest market share. In addition, diagnostic labs among the end users is projected to be dominating segment. The global renal biomarker market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The North America is expected to be dominating in the renal biomarker market owing to the presence of high quality healthcare infrastructure. In addition, prevalence rate of renal diseases is high in this region. Europe is another significant market and holds a considerable market share in the global renal biomarker market. Some of the key players operating in the global renal biomarker market are Abbott Laboratories Inc., Astute Medical Inc., Beckman Coulter Inc., Novartis AG, Roche Diagnostics and several others. In order to sustain in the competitive market, these players adopt various strategies such as merger & acquisitions, expansions, joint ventures and product development and partnership and collaboration. For instance, Bristol-Myers Squibb in January 2017 along with the GeneCentric Diagnostics entered into a Biomarker Research Collaboration. The collaboration is to explore if the Cancer Subtype Platform (CSP) of the GeneCentric is capable of identifying translational biomarkers for Opdivo. OPDIVO (nivolumab) is used as an indication for the treatment of advanced renal cell carcinoma (RCC) patients who have received prior anti-angiogenic therapy. The report covers: • Comprehensive research methodology of global renal biomarker market. • This report also includes detailed and extensive market overview with key analyst insights. • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations. • Analysis of regional regulations and other government policies impacting the global renal biomarker market. • Insights about market determinants which are stimulating the global renal biomarker market. • Detailed and extensive market segments with regional distribution of forecasted revenues. • Extensive profiles and recent developments of market players. Browse full report at : https://www.omrglobal.com/ Related reports : https://www.omrglobal.com/ About orion market research: OMR is a market research company known for its qualitative and quantitative research reports. The company aims to provide business insights for decision making to the global clients. OMR provides syndicated and customized research reports, company profiling, consulting and other research-based services to global clients. The "Orion" in the name signifies rising up in the sky, the company is committed to provide valuable insights that will help its clients to rise and shine. OMR provide customer-centric reports which facilitate the subscribers to know their touch points which can be capitalized for their revenue growth and to gain a competitive edge. Media Contact Email: support@omrglobal.com India: +91-780-304- info@omrglobal.com +91-917-982- End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|